Why the study?
Can circulating microRNAs distinguish between heart failure phenotypes (HFrEF vs HFpEF) and non-HF controls?
Can circulating microRNAs distinguish between heart failure phenotypes (HFrEF vs HFpEF) and non-HF controls?
Specific circulating microRNAs can serve as potential biomarkers to distinguish heart failure from controls and differentiate between HFrEF and HFpEF, potentially outperforming NT-proBNP.
No takes yet. Share an insight, caveat, or question.
MicroRNA panels may distinguish HFrEF from HFpEF; leaves open prospective validation and clinical utility beyond NT-proBNP.
Wong et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: